Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)

Today's Pre-Open Stock Movers

Forty Seven, Inc. (Nasdaq: FTSV) 62% HIGHER; Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions.

Trillium Therapeutics Inc. (Nasdaq: TRIL) 52.5% HIGHER; gains on FTSV takeover by GILD

Applied DNA Sciences Inc. (NASDAQ: APDN) 45.6% HIGHER; announced today that the design of 4 DNA vaccine candidates will be produced for preclinical animal testing via the Companys proprietary PCR-based DNA (LinearDNA) manufacturing systems.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) 45% HIGHER; announced positive top-line results from the randomized Phase 3 BOSTON study evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy. The BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival (PFS). The median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%) increase in median PFS (hazard ratio=0.70; p=0.0066). There were no new safety signals on the SVd arm and there was no imbalance in deaths between the two arms in the study. The full top-line data will be submitted for presentation at upcoming medical meetings.

Biocept, Inc. (NASDAQ: BIOC) 35.3% LOWER; today announced that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 23,000,000 shares of its common stock at a price of $0.40 per share, for aggregate gross proceeds of approximately $9.2 million, in a registered direct offering priced at-the-market under Nasdaq rules.

Co-Diagnostics, Inc. (Nasdaq: CODX) 30% HIGHER; announced today that following a recent change to the Food and Drug Administrations (FDA) policy towards the coronavirus outbreak, the Companys coronavirus test kits are available to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) for use according to the FDA guidelines.

Dynavax Technologies Corporation (NASDAQ: DVAX) 19.4% HIGHER; announced it is collaborating with the University of Queensland (UQ) as part of a Coalition for Epidemic Preparedness (CEPI) initiative to develop a vaccine to prevent COVID-19. Dynavax is providing technical expertise and the Companys proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) 15.1% LOWER; announced that it has entered into definitive agreements with certain accredited and healthcare-focused institutional investors, including Armistice Capital, for the purchase in a registered direct offering of an aggregate of 2,093,750 ordinary shares of the Company and warrants to purchase up to an aggregate of 2,093,750 ordinary shares at a combined purchase price of $8.00 per share and associated warrant.

Novavax (NASDAQ: NVAX) 11% LOWER; filed a prospectus supplement with the Securities and Exchange Commission which contemplates the sale of up to $150,000,000 of shares of the Company’s common stock (the “Shares”) from time to time in at-the-market offerings pursuant to an At Market Issuance Sales Agreement with B. Riley FBR, Inc. (the “Sales Agent”), dated as of March 2, 2020 (the “March 2020 Sales Agreement”). Sales pursuant to the March 2020 Sales Agreement will be made only upon instructions by the Company to the Sales Agent, and the Company cannot provide any assurances that it will issue any Shares pursuant to the March 2020 Sales Agreement.

Twitter (NYSE: TWTR) 8.7% HIGHER; reports over the weekend that hedge fund Elliott Management built a stake in the company and is pushing for changes, including removal of its CEO Jack Dorsey.

Carnival (NYSE: CCL) 3.5% LOWER; cruise lines continue lower on coronavirus fears

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Meta earnings, IBM to acquire HashiCorp, U.S. GDP ahead - what's moving markets
• HashiCorp Inc (HCP) PT Raised to $35 at Piper Sandler